Shares of Aldeyra Therapeutics Inc (NASDAQ:ALDX) saw unusually-strong trading volume on Tuesday . Approximately 115,424 shares were traded during mid-day trading, an increase of 67% from the previous session’s volume of 68,988 shares.The stock last traded at $5.59 and had previously closed at $5.53.

A number of equities research analysts have commented on ALDX shares. Cowen and Company reiterated a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, May 10th. Stifel Nicolaus started coverage on Aldeyra Therapeutics in a research note on Friday, July 1st. They issued a “buy” rating and a $16.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $13.15.

The stock’s 50-day moving average price is $5.94 and its 200 day moving average price is $5.32. The firm’s market cap is $34.91 million.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Wednesday, August 10th. The biotechnology company reported ($0.41) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.03. On average, analysts predict that Aldeyra Therapeutics Inc will post ($1.69) earnings per share for the current fiscal year.

In other news, major shareholder Perceptive Advisors Llc purchased 700,000 shares of the stock in a transaction on Thursday, May 26th. The shares were acquired at an average price of $5.00 per share, for a total transaction of $3,500,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company is focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are caused by naturally occurring toxic chemical species known as free aldehydes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.